CEACAM5 and cancer: Currently, several cancer biomarkers, including carcinoembryonic antigen (CEA)5 and prostate-specific antigen (PSA)6, have been targeted in diagnostic and prognostic strategies, but these are rarely present at earlier stages of malignancy.